On July 15th, Gelunhui reported that Hanshang Group (600774.SH) fell more than 8%, hitting a new 2-month low at 7.18 yuan, with a total market value of 2.12 billion yuan. The company issued a pre-reduction announcement yesterday evening, expecting that the net income for the first half of the year will be around 8 million yuan, a year-on-year decrease of about 83.41%. During the reporting period, the company's subsidiary, Chengdu Dikang Pharmaceutical Co., Ltd. was affected by factors such as group procurement and rising prices of medicinal materials, resulting in reduced profits.
A股异动 | 汉商集团跌超8% 药材价格上涨 中期净利预降超八成
A-share anomaly | hanshang group fell more than 8%, medicinal material prices rose, and the net profit in the middle period is expected to decline by more than 80%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.